Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**MGC0109** is an investigational **injectable small-molecule metabolic agent** being developed within the Magnus Charitable Trust portfolio, with Magnus Oxygen identified as the associated portfolio company. Publicly available pipeline information indicates that it is being explored for **ischemia-reperfusion related conditions**, including **ST-elevation myocardial infarction**, **reperfusion injury**, **chronic heart failure**, **stroke**, and **kidney transplant or kidney injury**. The precise molecular target and detailed pharmacology have not been publicly disclosed; based on the available description, the program appears intended for **metabolic modulation during ischemia-reperfusion injury** and may relate conceptually to **targeted temperature management** or tissue-protective metabolic support rather than a defined validated target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on MGC0109.